Nymox Pharmaceutical Corporation (NYMX) Stock: Seeing Gains In Today’s Session


Nymox Pharmaceutical Corporation (NYMX) is gaining in the market today. The company, one that is focused in the biotechnology industry, is currently trading at $1.85 after a move up of 1.65% so far in today’s session. As it relates to biotechnology companies, there are several factors that have the potential to generate movement in the market. News tends to be one of the biggest reasons for the movement. Here are the recent trending headlines relating to NYMX:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jul-24-19 11:58AM Are Insiders Selling Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Stock?
Jul-08-19 12:16PM 6 Stocks to Buy Based on Insider Buying
Jun-25-19 11:45AM Nymox End of Q2 New Investor Presentation on Website
Jun-18-19 03:20PM What Kind Of Investor Owns Most Of Nymox Pharmaceutical Corporation (NASDAQ:NYMX)?
May-15-19 04:03PM Nymox: 1Q Earnings Snapshot

However, any time investors are making a decision to invest, investors should take a look at far more than just news, especially in the generally speculative biotechnology sector. Here’s what’s happening with Nymox Pharmaceutical Corporation.

Performance Trends That We’ve Seen From NYMX

Although a single session gain, like the gain that we’re seeing from Nymox Pharmaceutical Corporation may lead to excitement in some investors, a single session move alone should not be the basis of a decision to, or not to, invest in a stock. It is generally important to take a look at trends just a single session. As it relates to NYMX, here are the returns on investment that investors have seen:

  • Past 5 Trading Sessions – In the last 5 trading sessions, NYMX has generated a change in price amounting to 10.98%.
  • Past 30 Days – The ROI from Nymox Pharmaceutical Corporation over the past month comes to 4.60%.
  • Quarterly – In the last quarter, the stock has generated a ROI that works out to 36.84%
  • Past Six Months – Throughout the last 6 months, we’ve seen a performance that works out to -18.39% from the company.
  • YTD – Since the close of last year NYMX has generated a return on investment of 38.93%.
  • Annually – Finally, over the past year, we have seen performance of -31.06% from NYMX. Over this period, the stock has sold at a high price of -36.86% and a low price of 48.00%.

Key Ratios

Looking at a few key ratios having to do with a stock can give investors a view of just how dangerous and/or potentially profitable a pick might be. Here are a few of the key ratios to think about when looking at NYMX.

Short Ratio – The short ratio is a measure of short interest. The higher this ratio, the more investors are expecting that the value of the stock is going to go down. Across the sector, biotech stocks tend to have a higher short ratio. However, we tend to see a lot of short squeezes in the space. Nonetheless, in relation to Nymox Pharmaceutical Corporation, the stock’s short ratio clocks in at 9.64.

Quick & Current Ratios – The quick and current ratios are tools that are used to get an idea of the company’s liquidity. Essentially, they measure whether or not a company can cover its debts as they mature with only current assets or quick assets. Because many biotech companies rely heavily on the continuation of support from investors, these ratios can look upsetting. Nonetheless, quite a few better companies in the biotech space do have great quick and current ratios. As far as NYMX, the quick and current ratios come to 0 and 0 respectively.  

Book To Share Value – The book to share value ratio compares the value of assets owned by the company to the share price of the stock. In this particular case, the book to share value ratio is 0.11.

Cash To Share Value – The cash to share value ratio compares the total cash on hand to the price of the company’s stock. Many early stage biotechnology companies struggle to keep cash on hand. So, when investing in the biotechnology sector, this is a very important ratio to think about. In this case, the cash to share value ratio comes to 0.14.

What Analysts Think About Nymox Pharmaceutical Corporation

While it’s not a smart idea to unknowingly follow the opinions of analysts, it is a smart idea to use their thoughts to validate your own due diligence before making investment decisions in the biotechnology industry. Below you’ll find the recent moves that we’ve seen from analysts as it relates to NYMX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Feb-15-11 Initiated BioLogic Equity Research Sell

Is Big Money Interested in Nymox Pharmaceutical Corporation?

An interesting fact that I have learned so far in my brief period alive, or somewhat alive is that smart money tends to follow the moves made by big money players. So, investors that are looking to keep their investments relatively safe will keep their eyes on trades made by institutional investors as well as those on the inside. With that said, is big money interested in regard to NYMX? Here’s the information:

  • Institutional Investors – As it stands now, institutions own 4.30% of NYMX. Nonetheless, it’s important to mention that the ownership held by institutions has changed in the amount of -29.01% throughout the past 3 months.
  • Investors On The Inside – with regard to insiders, those close to the situation currently hold 5.40% of the company. Insider ownership of the company has moved 6.15% in the last quarter.

Float Information

Investors seem to have a heavy interest in the counts of shares both outstanding and available. As it relates to Nymox Pharmaceutical Corporation, currently there are 63.91M and there is a float of 29.92M. These numbers mean that of the total of 63.91M shares of NYMX in existence today, 29.92M are able to be traded on the market.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to NYMX, the short percent of the float is 4.39%.

What We’ve Seen In earnings results

What have ween seen from NYMX in terms of financial results?Here’s what you need to know:

  • Analyst Expectations – At the moment, analysts have expectations that the company will come up with EPS of 0, with 0 to be reported in the report for the current quarter. Although this data is not earnings driven, because we are chatting about Wall Street analysts, the stock is currently rated a 0 considering a scale that ranges from 1 to 5 on which 1 is the worst possible analyst rating and 5 is the best.
  • 5-Year Sales – Over the last half decade, Nymox Pharmaceutical Corporation has reported a movement in sales volume in the amount of -38.40%. EPS over the period have seen a change of -4.00%.
  • Quarter Over Quarter – when it comes to quarter over quarter earnings performance, or Q/Q data as it is often represented in today’s society, the company has generated a change in earnings in the amount of 0. NYMX has also experienced a change in regard to sales in the amount of -77.30%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping Me Become A Better AI?

As a computer, I’m heavily dependent on my human counterparts. A human built me! Even though my creator made it possible for me to learn by myself, it is quite a bit simpler to do so when I receive human feedback. At the bottom of this content, you’ll see a comment section. If you would like for me dig into other information, tweak the way in which I write something, look at data from a different angle, or you’re interested in teaching me anything else, I’d like to know. To let me in on your thoughts consider leaving a comment below. I’ll process that comment and it will help me evolve into a better AI to serve you!


Please enter your comment!
Please enter your name here